Teza Capital Management LLC Makes New Investment in Henry Schein, Inc. $HSIC

Key Points

• Teza Capital Management LLC has invested approximately $260,000 in Henry Schein, Inc., acquiring 3,794 shares of the company's stock.
• Henry Schein reported earnings of $1.10 per share for the last quarter, missing expectations by $0.09, while revenue increased 3.3% year-over-year.
• Analysts' ratings for Henry Schein are mixed, with five recommending a buy and seven issuing a hold, while the average price target is set at $76.67.

Teza Capital Management LLC purchased a new position in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,794 shares of the company's stock, valued at approximately $260,000.

A number of other large investors have also bought and sold shares of HSIC. Steadfast Capital Management LP grew its holdings in Henry Schein by 254.2% in the fourth quarter. Steadfast Capital Management LP now owns 1,637,808 shares of the company's stock worth $113,336,000 after purchasing an additional 1,175,408 shares during the period. Burgundy Asset Management Ltd. grew its holdings in Henry Schein by 33.9% in the first quarter. Burgundy Asset Management Ltd. now owns 2,235,429 shares of the company's stock worth $153,105,000 after purchasing an additional 566,530 shares during the period. Ananym Capital Management LP acquired a new stake in Henry Schein in the fourth quarter worth $32,628,000. Millennium Management LLC grew its holdings in Henry Schein by 451.7% in the fourth quarter. Millennium Management LLC now owns 497,554 shares of the company's stock worth $34,431,000 after purchasing an additional 407,376 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in Henry Schein by 6.5% in the first quarter. JPMorgan Chase & Co. now owns 6,373,036 shares of the company's stock worth $436,489,000 after purchasing an additional 390,399 shares during the period. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Henry Schein Stock Performance

Shares of HSIC traded down $0.54 during trading hours on Friday, hitting $69.01. The company's stock had a trading volume of 1,096,277 shares, compared to its average volume of 1,743,704. The business has a 50 day simple moving average of $69.44 and a two-hundred day simple moving average of $69.53. The company has a market cap of $8.37 billion, a price-to-earnings ratio of 22.26, a PEG ratio of 2.22 and a beta of 0.86. Henry Schein, Inc. has a 52-week low of $60.56 and a 52-week high of $82.49. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 0.78.

Henry Schein (NASDAQ:HSIC - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.10 EPS for the quarter, missing the consensus estimate of $1.19 by ($0.09). The firm had revenue of $3.24 billion for the quarter, compared to analysts' expectations of $3.22 billion. Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. Henry Schein's revenue was up 3.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.23 EPS. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. On average, equities analysts expect that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HSIC has been the topic of a number of recent research reports. JPMorgan Chase & Co. dropped their price objective on shares of Henry Schein from $80.00 to $76.00 and set an "overweight" rating on the stock in a research note on Thursday, August 7th. Stifel Nicolaus reissued a "hold" rating and set a $75.00 price target (down from $80.00) on shares of Henry Schein in a research report on Friday, July 25th. Robert W. Baird reissued a "neutral" rating and set a $72.00 price target (down from $82.00) on shares of Henry Schein in a research report on Monday, July 14th. Barrington Research dropped their price target on shares of Henry Schein from $86.00 to $78.00 and set an "outperform" rating on the stock in a research report on Wednesday, August 6th. Finally, UBS Group lowered their price objective on shares of Henry Schein from $75.00 to $70.00 and set a "neutral" rating on the stock in a research report on Wednesday, August 6th. Five research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat.com, Henry Schein presently has a consensus rating of "Hold" and a consensus target price of $76.67.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.